Ushio KK engages in the management of retail supermarkets. The company was founded in May 1946 and is headquartered in Izumo, Japan.

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of the world’s leading labs. Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Their expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today their focus is on HIV but our methods and expertise can be applied to other viruses. Cavidi’s head office is in Uppsala, Sweden and they have sales offices in South Africa, India and USA. Their customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.

Biomune Co., a subsidiary of CEVA Sant�� Animale SA, is a company headquartered in Lenexa, KS, that manufactures poultry vaccines. On June 17, 2005 CEVA Sant�� Animale SA acquired Biomune Co. from ZEON Corp.

Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

PathogenDx has developed a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets. Our technology allows test labs to conduct between 12- 48 tests in parallel, testing up to 20 pathogens per test in less than a days’ shift. This is done at a fraction of the cost of plate counts or Realtime PCR. Our Raw Sample technology allows laboratories to bypass almost 20 steps that Real-time PCR must perform for DNA extraction and purification. PathogenDx technology bypasses the need for purification, quantitation, and normalization increasing the speed and affordability of pathogen screening. This helps our customers reduce testing time by 12 hours on the front end, and avoid spending money on sample prep kits and additional instrumentation.

Gilead Pharmasset LLC, part of Gilead Sciences, Inc., is a company headquartered in Princeton, NJ, that discovers, develops and commercializes therapeutic products and treatments for viral diseases.

Miles is a mobile app that automatically tracks and logs mileage for business purposes. Miles users can now create and export their mileage logs without the need of manual input.

Symantec, Inc. is a private company headquartered in Burlington, MA. The firm provides computer security services.

Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease, Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.

Bio Products Laboratory Ltd. manufactures blood plasma products. It offers products that are classified in human coagulation factors, human immunoglobulins, and human albumin solutions. The company was founded on August 11, 1950 and is headquartered in Elstree, the United Kingdom.

Graffinity Pharmaceuticals AG specializes in chemical genomics pharmaceutical products. Through its fragment based chemical genomics platform, it provides novel small molecules for drug discovery and chemical genomics approaches. The company was founded in 1998 and is headquartered in Heidelberg, Germany.

Alpha Therapeutic Corp., a subsidiary of Grifols SA /Grifols Family/, is an American company located in Los Angeles, CA. The firm develops of plasma derived products.

uvoton Technology was founded to bring customers new solutions inspired by innovation. The company was spun-off as a Winbond affiliate in 2008 while Winbond continues to focus on its large Memory business. From those beginnings we are relatively new up-and-coming digital/analog/mixed signal semiconductor company. Public since just September 27, 2010 on the Taiwan Stock Exchange (TSE) , we are bringing new solutions to our customers that change the world around us. The Nuvoton portfolio includes products previously under Winbond and those that have grown organically including: Computer: Super IO (SIO) , Embedded Controllers (EC) , Trusted Platform Modules (TPM) , Power Management among others. We are one of the world's top three suppliers of Super IO, Embedded Controllers and Trusted Platform Modules for the PC industry. Microcontrollers: ARM® Cortex™ M0 plus ARM® 7/ ARM® 9 with others in development plus 8051 families. We are a leader in microcontrollers with our new fast growing portfolio of ARM® Cortex™ microcontrollers plus a family of 8051 products. These families currently include a wide range of ARM® controllers including Cortex™ M0, ARM® 7/ ARM® 9 with more to come. Mixed Signal: Speech Playback and Record Products with embedded Flash. Audio Products including Power Amplifiers, Audio ADC's/DAC's and CODECS. We also lead the industry with extremely high fidelity solutions for speech recording/playback and full range audio applications that serve consumer, automotive, white goods and other markets. Headquartered in Hsinchu, Taiwan, Nuvoton has subsidiaries in the U.S.A., Mainland China, Israel,and India to strengthen regional support and global management.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Sangfor Technology Co., Ltd., established on 2000-12-25, Business scope includes general business items:,The licensing program is:Research and development of computer hardware and software,Production,Sales and related technical services;Research and development of network products,Production,Sales and related technical services;Computer information system integration and related technical consultation(None of the above exclusive,Exclusive control,Exclusives and restricted items);Export of goods and technology(without distribution);The first type of value-added telecommunications services;The second type of value-added telecommunications services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Baxter AG, part of Baxter International, Inc., is a company headquartered in Volketswell, Switzerland. The firm wholesales pharmaceutical products.

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.